This combination is now approved not only in wild-type BRAF V600 melanoma, but also for patients with unresectable or metastatic melanoma regardless of BRAF status; for previously untreated patients with intermediate- and poor-risk advanced renal cell carcinoma; and for previously treated microsatellite instability high/mismatch repair deficient metastatic colorectal cancer, where high microsatellite instability or mismatch repair deficiency served as biomarkers. This evidence concerns the gene BRAF and renal cell carcinoma.